Particles and powders: Tools of innovation for non-invasive drug administration

Journal of Controlled Release

Volumn 161, Issue 2, 2012, Pages 693-702

  Buttini, Francesca ^a   Colombo, Paolo ^a   Rossi, Alessandra ^a   Sonvico, Fabio ^a   Colombo, Gaia ^b  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

Author keywords

Agglomerate; Inhalation; Microparticle; Nasal; Oral delivery; Powder

Indexed keywords

AGGLOMERATE; INHALATION; MICRO PARTICLES; NASAL; ORAL DELIVERY;

POWDERS;

DRUG DOSAGE;

BENZOIC ACID; BILE SALT; BOVINE SERUM ALBUMIN; CHITOSAN; CINNARIZINE; CYCLODEXTRIN; EUDRAGIT; GENTAMICIN; HEPARIN; HYALURONIC ACID; INSULIN; MESALAZINE; PHOSPHOLIPID; POLYMER; POLYVINYL ALCOHOL; POVIDONE; SALBUTAMOL SULFATE; SURFACTANT; THEOPHYLLINE;

AREA UNDER THE CURVE; CRYSTALLIZATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG SOLUBILITY; FOOD PACKAGING; HUMAN; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PARTICLE SIZE; PATIENT COMPLIANCE; POWDER; PRIORITY JOURNAL; REVIEW;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ANIMALS; HUMANS; NEBULIZERS AND VAPORIZERS; PHARMACEUTICAL PREPARATIONS; POWDERS;

EID: 84862677852     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2012.02.028     Document Type: Review

References (87)

1. M.L. Tan, P.F. Choong, C.R. Dass, Recent developments in liposomes, microparticles and nanoparticles for protein and peptide drug delivery, Peptides 31 (2010) 184-193.
2. C.M. Lopes, P. Martins-Lopes, E.B. Souto, Nanoparticulate carriers (NPC) for oral pharmaceutics and nutraceutics, Pharmazie 65 (2010) 75-82.
3. V.T. Tran, J.P. Benoît, M.C. Venier-Julienne, Why and how to prepare biodegradable, monodispersed, polymeric microparticles in the field of pharmacy? Int. J. Pharm. 407 (2011) 1-11.
4. J. Wang, J.D. Byrne, M.E. Napier, J.M. DeSimone, More effective nanomedicines through particle design, Small 7 (2011) 1919-1931.
5. Q.T. Zhou, B. Armstrong, I. Larson, P.J. Stewart, D.A. Morton, Understanding the influence of powder flowability, fluidization and de-agglomeration characteristics on the aerosolization of pharmaceutical model powders, Eur. J. Pharm. Sci. 40 (2010) 412-421.
6. A. Adebisi, B.R. Conway, Gastroretentive microparticles for drug delivery applications, J. Microencapsul. 28 (2011) 689-708.
7. D.S. Pisal, M.P. Kosloski, S.V. Balu-Iyer, Delivery of therapeutic proteins, J. Pharm. Sci. 99 (2010) 2557-2575.
8. R. Singh, J.W. Lillard, Nanoparticle-based targeted drug delivery, Exp. Mol. Pathol. 86 (2009) 215-223.
9. D.A. Mitchison, P.B. Fourie, The near future: improving the activity of rifamycins and pyrazinamide, Tuberculosis 90 (2010) 177-181.
10. M. Rieder, If children ruled the pharmaceutical industry: the need for pediatric formulations, Drug News Perspect. 23 (2010) 458-464.
11. S.G.Dubois, S. Shusterman, J.M. Reid,A.M. Ingle, C.H.Ahern, S. Baruchel, J.Glade-Bender, P. Ivy, P.C. Adamson, S.M. Blaney. Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study, Cancer Chemother. Pharmacol. (article in press, doi:10.1007/s00280-011-1798-2) [Electronic publication ahead of print].
12. European Medicines Agency (EMA) - Committee for Medicinal Products for Human Use (CHMP), Reflection Paper: Formulations of Choice for the Pediatric Population, EMEA/CHMP/PEG/194810/2005, 2006.
13. S.R. Craig, L.V. Adams, S.P. Spielberg, B. Campbell, Pediatric therapeutics and medicine administration in resource-poor settings: a review of barriers and an agenda for interdisciplinary approaches to improving outcomes, Soc. Sci. Med. 69 (2009) 1681-1690.
14. J. Hamman, J. Steenekamp, Excipients with specialized functions for effective drug delivery, Expert Opin. Drug Deliv. 9 (2012) 219-230.
15. W. Kaialy, M.N. Momin, M.D. Ticehurst, J. Murphy, A. Nokhodchi, Engineered mannitol as an alternative carrier to enhance deep lung penetration of salbutamol sulphate from dry powder inhaler, Colloids Surf. B Biointerfaces 79 (2010) 345-356.
16. Z.H. Loh, D.Z.L. Er, L.W. Chan, C.V. Liew, P.W.S. Heng, Spray granulation for drug formulation, Expert Opin. Drug Deliv. 8 (2011) 1645-1661.
17. H.K. Chan, P.C. Kwok, Production methods for nanodrug particles using the bottom-up approach, Adv. Drug Deliv. Rev. 63 (2011) 406-416.
18. E. Kougoulos, I. Smales, H.M. Verrier, Towards integrated drug substance and drug product design for an active pharmaceutical ingredient using particle engineering, AAPS PharmSciTech 12 (2011) 287-294.
19. J.H. Jeong, T.G. Park, S.H. Kim, Self-assembled and nanostructured siRNA delivery systems, Pharm. Res. 28 (2011) 2072-2085.
20. K. Bowey, R.J. Neufeld, Systemic and mucosal delivery of drugs within polymeric microparticles produced by spray drying, BioDrugs 24 (2010) 359-377.
21. A. Berton, G. Piel, B. Evrard, Powdered lipid nano and microparticles: production and applications, Recent Pat. Drug Deliv. Formul. 5 (2011) 188-200.
22. X. Lin, C.W. Chyi, K.F. Ruan, Y. Feng, P.W. Heng, Development of potential novel cushioning agents for the compaction of coated multi-particulates by coprocessing micronized lactose with polymers, Eur. J. Pharm. Biopharm. 79 (2011) 406-415.
23. A. Dolenc, J. Kristl, S. Baumgartner, O. Planinsek, Advantages of celecoxib nanosuspension formulation and transformation into tablets, Int. J. Pharm. 376 (2009) 204-212.
24. P. Russo, F. Buttini, F. Sonvico, R. Bettini, G. Massimo, C. Sacchetti, P. Colombo, P. Santi, Chimeral agglomerates of microparticles for the administration of caffeine nasal powders, J. Drug Del. Sci. Tech. 14 (2004) 449-454.
25. X. Li, N. Anton, T. Ta, M. Zhao, N. Messaddeq, T.F. Vandamme, Microencapsulation of nanoemulsions: novel Trojan particles for bioactive lipid molecule delivery, Int. J. Nanomedicine 6 (2011) 1313-1325.
26. H. Yoshida, H. Ito, Y. Soeda, Soft-pellet drug and process for their preparation thereof, WO9927911 A1 (1999).
27. P. Srinarong, H. de Waard, H.W. Frijlink, W.L. Hinrichs, Improved dissolution behavior of lipophilic drugs by solid dispersions: the production process as starting point for formulation considerations, Expert Opin. Drug Deliv. 8 (2011) 1121-1140.
28. M. Messner, S.V. Kurkov, P. Jansook, T. Loftsson, Self-assembled cyclodextrin aggregates and nanoparticles, Int. J. Pharm. 387 (2010) 199-208.
29. V.N.P. Le, E. Robins, M.P. Flament, Agglomerate behaviour of fluticasone propionate within dry powder inhaler formulations, Eur. J. Pharm. Biopharm. 80 (2012) 596-603.
30. Y. Wang, K. Kho, W.S. Cheow, K. Hadinoto, A comparison between spray drying and spray freeze drying for dry powder inhaler formulation of drug-loaded lipid-polymer hybrid nanoparticles, Int. J. Pharm. 424 (2012) 98-106.
31. R.G. Strickley, Q. Iwata, S. Wu, T.C. Dahl, Pediatric drugs - a review of commercially available oral formulations, J. Pharm. Sci. 97 (2008) 1731-1774.
32. G. Di Pretoro, L. Zema, A. Gazzaniga, S.L. Rough, D.I. Wilson, Extrusion-spheronisation of highly loaded 5-ASA multiparticulate dosage forms, Int. J. Pharm. 402 (2010) 153-164.
33. I. Stoltenberg, J. Breitkreutz, Orally disintegrating mini-tablets (ODMTs) - a novel solid oral dosage form for paediatric use, Eur. J. Pharm. Biopharm. 78 (2011) 462-469.
34. P.S. Hiremath, K.S. Soppimath, G.V. Betageri, Proliposomes of exemestane for improved oral delivery: formulation and in vitro evaluation using PAMPA, Caco-2 and rat intestine, Int. J. Pharm. 380 (2009) 96-104.
35. S.R. Kim, J.K. Kim, J.S. Park, C.K. Kim, Dry elixir formulations of dexibuprofen for controlled release and enhanced oral bioavailability, Int. J. Pharm. 404 (2011) 301-307.
36. M.A. Alhnan, S. Murdan, A.W. Basit, Encapsulation of poorly soluble basic drugs into enteric microparticles: a novel approach to enhance their oral bioavailability, Int. J. Pharm. 416 (2011) 55-60.
37. J.G. Still, Development of oral insulin: progress and current status, Diabetes Metab. Res. Rev. 18 (2002) S29-S37.
38. H. Chung, J. Kim, J.Y. Um, I.C. Kwon, S.Y. Jeong, Self-assembled 'nanocubicle' as a carrier for peroral delivery, Diabetologia 45 (2002) 448-451.
39. M. Kipnes, P. Dandona, D. Tripathy, J.G. Still, G. Kosutic, Control of postprandial plasma glucose by an oral product (HMI2) in patients with type 2 diabetes, Diabetes Care 26 (2003) 421-426.
40. S. Sajeesh, K. Bouchemal, V. Marsaud, C. Vauthier, C.P. Sharma, Cyclodextrin complexed insulin encapsulated hydrogel microparticles: an oral delivery system for insulin, J. Control. Release 147 (2010) 377-384.
41. P.J. Salústio, P. Pontes, C. Conduto, I. Sanches, C. Carvalho, J. Arrais, H.M. Cabral Marques, Advanced technologies for oral controlled release: cyclodextrins for oral controlled release, AAPS PharmSciTech 12 (2011) 1276-1292.
42. A. Lamprecht, N. Ubrich, P. Maincent, Oral low molecular weight heparin delivery by microparticles from complex coacervation, Eur. J. Pharm. Biopharm. 67 (2007) 632-638.
43. J. Breitkreutz, M. Bornhöft, F. Wöll, P. Kleinebudde, Pediatric drug formulations of sodium benzoate: I. Coated granules with a hydrophilic binder, Eur. J. Pharm. Biopharm. 56 (2003) 247-253.
44. J. Breitkreutz, F. El-Saleh, C. Kiera, P. Kleinebudde, W. Wiedey, Pediatric drug formulations of sodium benzoate: II. Coated granules with a lipophilic binder, Eur. J. Pharm. Biopharm. 56 (2003) 255-260.
45. A.G. Balducci, G. Colombo, G. Corace, C. Cavallari, L. Rodriguez, F. Buttini, P. Colombo, A. Rossi, Layered lipid microcapsules for mesalazine delayed-release in children, Int. J. Pharm. 421 (2011) 293-300.
46. R.P. Raffin, P. Colombo, F. Sonvico, G. Colombo, A. Rossi, F. Buttini, Compositions in powder form made of soft agglomerates of a micronized drug and of a twocomponents excipient, and process for their preparation, WO2009/052869 A1 (2009).
47. R.P. Raffin, P. Colombo, F. Sonvico, F.S. Polleto, G. Colombo, A. Rossi, A.R. Pohlmann, S.S. Guterres, Soft agglomerates of pantoprazole gastro-resistant microparticles for oral administration and intestinal release, J. Drug Del. Sci. Tech. 17 (2007) 407-413.
48. R.P. Raffin, L.M. Colomé, C.R.D. Hoffmeister, P. Colombo, A. Rossi, F. Sonvico, L.M. Colomé, C.C. Natalini, A.R. Pohlmann, T. Dalla Costa, S.S. Guterres, Pharmacokinetics evaluation of soft agglomerates for prompt delivery of enteric pantoprazoleloaded microparticles, Eur. J. Pharm. Biopharm. 74 (2010) 275-280.
49. C. Bitter, K. Suter-Zimmermann, C. Surber, Nasal drug delivery in humans, Curr. Probl. Dermatol. 40 (2011) 20-35.
50. A. Pires, A. Fortuna, G. Alves, A. Falcao, Intranasal drug delivery: how, why and what for? J. Pharm. Pharm. Sci. 12 (2009) 288-311.
51. L. Illum, Transport of drugs from the nasal cavity to the central nervous system, Eur. J. Pharm. Sci. 11 (2000) 1-18.
52. D. Fitzgerald, R.J. Mrsny, New approaches to antigen delivery, Crit. Rev. Ther. Drug Carrier Syst. 17 (2000) 165-248.
53. G. Colombo, L. Lorenzini, E. Zironi, V. Galligioni, F. Sonvico, A.G. Balducci, G. Pagliuca, A. Giuliani, L. Calzà, A. Scagliarini, Brain distribution of ribavirin after intranasal administration, Antiviral Res. 92 (2011) 408-414.
54. E. Marttin, S.G. Romeijn, J.C. Verhoef, F.W.H.M. Merkus, Nasal absorption of dihydroergotamine from liquid and powder formulations in rabbits, J. Pharm. Sci. 86 (1997) 802-807.
55. N. Fransen, S. Bredenberg, E. Bjork, Clinical study shows improved absorption of desmopressin with novel formulation, Pharm. Res. 26 (2009) 1618-1625.
56. H. Kublik, M.T. Vidgren, Nasal delivery systems and their effect on deposition and absorption, Adv. Drug Deliv. Rev. 29 (1998) 157-177.
57. E. Pringels, C. Callens, C. Vervaet, F. Dumont, G. Slegers, P. Foreman, J.P. Remon, Influence of deposition and spray pattern of nasal powders on insulin bioavailability, Int. J. Pharm. 310 (2006) 1-7.
58. P.G. Djupesland, A. Skretting, M. Winderen, T. Holand, Bi-directional nasal delivery of aerosol can prevent lung deposition, J. Aerosol Med. 17 (2004) 249-259.
59. P.G. Djupesland, P. Docekal, Intranasal sumatriptan powder delivered by a novel breath actuated bi-directional device for the acute treatment of migraine: a randomised, placebo-controlled study, Cephalalgia 30 (2010) 933-942.
60. F.S. Hansen, P.G. Djupesland, W.J. Fokkens, Preliminary efficacy of fluticasone delivered by a novel device in recalcitrant chronic rhinosinusitis, Rhinology 48 (2010) 292-299.
61. C. Sacchetti, M. Artusi, P. Santi, P. Colombo, Caffeine microparticles for nasal administration obtained by spray drying, Int. J. Pharm. 242 (2002) 335-339.
62. P. Russo, C. Sacchetti, I. Pasquali, R. Bettini, G. Massimo, P. Colombo, A. Rossi, Primary microparticles and agglomerates of morphine for nasal insufflation, J. Pharm. Sci. 95 (2006) 2553-2561.
63. F. Ishikawa, M. Katsura, I. Tamai, A. Tsuji, Improved nasal bioavailability of elcatonin by insoluble powder formulation, Int. J. Pharm. 224 (2001) 105-114.
64. F. Ishikawa, M. Murano, M. Hiraishi, T. Yamaguchi, I. Tamai, A. Tsuji, Insoluble powder formulation as an effective nasal drug delivery system, Pharm. Res. 19 (2002) 1097-1104.
65. V.D. Romeo, J.C. deMeireles, W.J. Gries, W.J. Xia, A.P. Sileno, H.K. Pimplaskar, C.R. Behl, Optimization of systemic nasal drug delivery with pharmaceutical excipients, Adv. Drug Deliv. Rev. 29 (1998) 117-133.
66. S.S. Davis, L. Illum, Absorption enhancers for nasal drug delivery, Clin. Pharmacokinet. 42 (2003) 1107-1128.
67. M.I. Ugwoke, R.U. Agu, N. Verbeke, R. Kinget, Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives, Adv. Drug Deliv. Rev. 57 (2005) 1640-1665.
68. S.T. Lim, B. Forbes, D.J. Berry, G.P. Martin, M.B. Brown, In vivo evaluation of novel hyaluronan/chitosan microparticulate delivery systems for the nasal delivery of gentamicin in rabbits, Int. J. Pharm. 231 (2002) 73-82.
69. L. Illum, I. Jabbal-Gill, M. Hinchcliffe, A.N. Fisher, S.S. Davis, Chitosan as a novel nasal delivery system for vaccines, Adv. Drug Deliv. Rev. 51 (2001) 81-96.
70. C. Prego, D. Torres, M.J. Alonso, Chitosan nanocapsules: a new carrier for nasal peptide delivery, J. Drug Del. Sci. Tech. 16 (2006) 331-337.
71. L. Illum, Nanoparticulate system for nasal delivery of drugs: a real improvement over simple systems? J. Pharm. Sci. 96 (2007) 473-483.
72. Y.J. Son, J.T. McConville, Advancements in dry powder delivery to the lung, Drug Dev. Ind. Pharm. 34 (2008) 948-959.
73. N. Islam, E. Gladki, Dry powder inhalers (DPIs) - a review of device reliability and innovation, Int. J. Pharm. 360 (2008) 1-11.
74. G. Buckton, Characterisation of small changes in the physical properties of powders of significance for dry powder inhaler formulations, Adv. Drug Deliv. Rev. 26 (1997) 17-27.
75. A.H. Chow, H.H. Tong, P. Chattopadhyay, B.Y. Shekunov, Particle engineering for pulmonary drug delivery, Pharm. Res. 24 (2007) 411-437.
76. R. Vehring, Pharmaceutical particle engineering via spray drying, Pharm. Res. 25 (2008) 999-1022.
77. D.E. Geller, J. Weers, S. Heuerding, Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™technology, J. Aerosol Med. Pulm. Drug Deliv. 24 (2011) 175-182.
78. M. Asada, H. Takahashi, H. Okamoto, H. Tanino, K. Danjo, Theophylline particle design using chitosan by the spray drying, Int. J. Pharm. 270 (2004) 167-174.
79. L. Wu, B. Bharatwaj, J. Panyam, S.R.P. da Rocha, Core-shell particles for the dispersion of small polar drugs and biomolecules in hydrofluoroalkane propellants, Pharm. Res. 25 (2008) 289-301.
80. H.Y. Li, P.C. Seville, Novel pMDI formulations for pulmonary delivery of proteins, Int. J. Pharm. 385 (2010) 73-78.
81. X.M. Zeng, G.P. Martin, S.K. Tee, C. Marriott, The role of fine particle lactose on the dispersion and deaggregation of salbutamol sulphate in an air stream in vitro, Int. J. Pharm. 176 (1998) 99-110.
82. A.M. Boshhiha, N.A. Urbanetz, Influence of carrier surface fines on dry powder inhalation formulations, Drug Dev. Ind. Pharm. 35 (2009) 904-916.
83. K. Lida, Y. Hayakawa, H. Okamoto, K. Danjo, H. Luenberger, Effect of surface layering time of lactose carrier particles on dry powder inhalation properties of salbutamol sulfate, Chem. Pharm. Bull.(Tokyo) 52 (2004) 350-353.
84. F. Ferrari, D. Cocconi, R. Bettini, F. Giordano, P. Santi, M. Tobyn, R. Price, P. Young, C. Caramella, P. Colombo, The surface roughness of lactose particles can be modulated by wet-smoothing using a high-shear mixer, AAPS PharmSciTech 5 (2004) 69-74.
85. F. Buttini, P. Colombo, M.P. Wenger, P. Mesquida, C. Marriott, S.A. Jones, Back to basics: the development of a simple, homogenous, two-component dry-powder inhaler formulation for the delivery of budesonide using miscible vinyl polymers, J. Pharm. Sci. 97 (2008) 1257-1267.
86. X.M. Zeng, A.P. Martin, C. Marriott, J. Pritchard, The influence of carrier morphology on drug delivery by dry powder inhalers, Int. J. Pharm. 200 (2000) 93-106.
87. M.J. Donovan, H.D. Smyth, Influence of size and surface roughness of large lactose carrier particles in dry powder inhaler formulations, Int. J. Pharm. 402 (2010) 1-9.